Imipenem + Cilastatina Color

Imipenem/cilastatin, the active ingredient in Imipenem + Cilastatina Color, is a carbapenem antibiotic presented as an intravenous solution for injection. It treats severe bacterial infections, including complicated intra‑abdominal, urinary tract, skin and soft‑tissue infections, nosocomial pneumonia, and febrile neutropenia in hospitalized patients. It is indicated for use in adult and pediatric patients when susceptible pathogens are identified.

GNH USA supplies Imipenem + Cilastatina Color as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and clinical use.

Imipenem/cilastatin is a broad‑spectrum carbapenem antibiotic used to treat serious bacterial infections.

- Complicated intra‑abdominal infections: achieves bacterial eradication in the peritoneal cavity and reduces infection‑related morbidity. - Complicated urinary tract infections: clears resistant uropathogens and improves renal outcomes. - Skin and soft‑tissue infections: provides rapid bacterial clearance in deep tissue infections. - Nosocomial pneumonia: penetrates lung tissue to treat hospital‑acquired respiratory infections. - Febrile neutropenia: offers broad coverage for Gram‑negative and Gram‑positive organisms in immunocompromised patients.

Adverse reactions may occur with imipenem/cilastatin therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal discomfort. - Diarrhea: may be watery and self‑limiting. - Rash: erythematous skin eruption. - Headache: transient cranial discomfort. - Elevated liver enzymes: mild transaminase increase.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Anaphylaxis: acute hypersensitivity requiring emergency care. - Clostridioides difficile infection: severe colitis risk. - Stevens‑Johnson syndrome: rare mucocutaneous reaction. - Severe neutropenia: marked reduction in white blood cells.

Use of imipenem/cilastatin requires careful clinical monitoring.

- Assess renal function: dose adjustment may be needed in renal impairment. - Monitor for seizures: avoid in patients with a history of CNS disorders. - Evaluate hypersensitivity: discontinue if an allergic reaction occurs. - Use caution with concomitant valproic acid: may reduce seizure control. - Adjust dose in pediatric patients: follow prescriber guidance. - Store at below 25°C: keep in the original pack, protect from moisture.

Imipenem/cilastatin can interact with several medicines.

Major Interactions (Avoid): - Valproic acid: carbapenems reduce serum valproate levels, risking breakthrough seizures. - Probenecid: may increase imipenem concentrations, heightening toxicity risk. - Monoamine oxidase inhibitors: combined use may lower seizure threshold.

Moderate Interactions (Monitor Closely): - Diuretics: may exacerbate renal electrolyte disturbances. - NSAIDs: concurrent use can affect renal function. - Rifampin: may alter imipenem metabolism, requiring monitoring.